Osteotec Limited obtain FDA registration for ChiroKlip

Osteotec Limited has announced that they have obtained FDA registration for ChiroKlip, the powerful self-fixing disposable device that solves the problem of protecting the protruding ends of K-wires.

ChiroKlip joins the Osteotec Silicone Finger and Concentric Bone Graft System as a new member of the range of high-quality, Osteotec products available in the USA market within the orthopedic space.

Osteotec is working to secure a distribution network for ChiroKlip across the US, as well as continuing to successfully expand in areas outside of the USA.

What is ChiroKlip? 

ChiroKlip is a new concept in solving the perennial problem of protecting the protruding ends of K-wires and is a powerful self-fixing disposable device developed in the UK.

The butterfly-shaped clip is simple to use and protects the exposed end of the K-wire without using old-fashioned and inefficient corks or strapping, or complicated instrumentation.

Protecting the end of the K-wire with ChiroKlip can help prevent trauma or tearing of clothing or other items. The single-use ChiroKlip also helps in the removal of wires by allowing an excellent purchase on the wire.

ChiroKlip is widely used within UK hospitals and has a growing export market. Available in easy-to-use boxes of 25 packs, with each pack containing 2 gamma sterilized ChiroKlips.

“FDA registration for ChiroKlip will mean that all Osteotec own-manufactured devices can be sold in the USA, presenting a great opportunity for our export business,” said Andrew Dubowski, Osteotec Commercial Director.

“Osteotec products offer excellent commercial opportunities for orthopedic sales organizations in the USA. Adding our devices to your portfolio is a great way to offer a comprehensive solution to surgeons.”

Matt Woods, Osteotec Managing Director, said: “ChiroKlip is a fantastic addition to the Osteotec family, complementing and strengthening our existing product line. This is the latest acquisition Osteotec has made as we continue to grow our international offering.”

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”